ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1442

IRF-1 Deficient Lupus-Prone MRL/Lpr Mice Show Reduced Glomerulonephritis but Develop Severe Interstitial Nephritis, Renal Vasculitis and Pulmonary Granulomas with Propensity for Th2 Polarity

Hidemaru Sekine1, Takeshi Machida1, Natsumi Sakamoto1, Eiji Suzuki2, Xian Zhang3, Christopher Reilly4 and Gary S. Gilkeson5, 1Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan, 2Medicine, Medical University of South Carolina, Charleston, SC, 3Medicine, Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC, 4Virginia Tech, Blacksburg, VA, 5Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Animal models, lupus nephritis and systemic lupus erythematosus (SLE), T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: The transcription factor interferon regulatory factor-4 (IRF-4) and -1 (IRF-1) are members of the IRF family of transcription regulators and involved in the development of Th2/Th17 and Th1 cells, respectively. MRL/lpr mice, a murine model of human SLE, spontaneously develop lupus-like disease. At ACR 2011, we reported that Irf4-/- MRL/lpr mice, which lacked serum autoantibodies and Th17 cells, developed proliferative glomerulonephritis but minimal to no interstitial nephritis or renal vasculitis. Irf4-/- MRL/lpr mice also developed granulomas containing Langhans-type multinucleated giant cells (MGCs) in multiple organs with significantly increased numbers of IFN-γ producing CD4+ T cells, suggesting autoreactive Th1 cell-mediated mechanisms for their pathogenesis. To further define the role of autoreactive CD4+ T cells in murine lupus, we generated Irf1-/- MRL/lpr mice and assessed their disease.

Methods: Irf1-/- MRL/lpr mice were generated by backcrossing Irf1–KO C57BL/6 mice onto MRL/lpr background for 7 generations by using speed congenic strategy. Mice were sacrificed at 18 weeks of age and histopathological analysis in multiple organs was performed. Infiltration of CD4+ T cells and CD68+ macrophages/monocytes in tissues was detected by immunofluorescence or immunohistochemical staining. Splenic immune cell populations were analyzed by flow. To determine Th1/Th2/Th17 cell numbers, splenic CD4+T cells were cultured with PMA/ionomycin, and IFN-γ, IL-4 or IL-17 production was detected by intracellular staining and flow analysis.

Results: Unlike WT or Irf4-/- MRL/lpr mice, Irf1-/- MRL/lpr mice showed severe inflammation in their renal intersititum and blood vessels characterized by predominant infiltration of CD4+ T cells. In contrast, minimal to no inflammation was observed in their glomeruli, suggesting independent mechanisms for development of interstitial nephritis and renal vasculitis. Irf1-/- MRL/lpr mice also developed pulmonary granulomas characterized by predominant infiltration of CD68+ macrophages/epithelioid cells with formation of foreign body-type and Langhans-type MGCs. No granuloma was observed in age-matched WT MRL/lpr or Irf1-/- C57BL/6 mice. Different appearances of renal disease and granulomas between Irf4-/- and Irf1-/- MRL/lpr mice are summarized in the table. Intracellular cytokine analysis showed that there was significantly increased population of IL-4-producing CD4+ T cells in the spleens of Irf1-/- MRL/lpr and C57BL/6 mice than their WT controls.     

Conclusion: Our results indicate that IRF-1 plays an important role in the regulation of Th2 polarity in MRL/lpr and C57BL/6 mice. Development of inflammatory renal disease and pulmonary granulomas not in Irf1-/- C57BL/6 mice but in lupus-prone Irf1-/- MRL/lpr mice with significantly increased numbers of IL-4 producing CD4+ T cells suggests autoreactive Th2 cell-mediated mechanisms for their pathogenesis.

CD4+ T cell polarity  Renal disease Granulomas
Mouse

Glomerular change

Interstitial inflamation Vasculitis Lung Liver Spleen Lymph node
Irf4-/- MRL/lpr

    Th1

±~++(Proliferative GN)

−~± None CD4+ T cell predominant infiltration with formation of Langhans-type MGCs CD4+ T cell predominant infiltration with formation of Langhans-type MGCs CD4+ T cell predominant infiltration with formation of few Langhans-type MGCs CD4+ T cell predominant infiltration with formation of few Langhans-type MGCs
Irf1-/- MRL/lpr

    Th2

−~±

+++       CD4+ T cell predominant infiltration 

+++       CD4+ T cell predominant infiltration  CD68+ macrophages predominant infiltration with formation of foreign body-type and Langhans-type MGCs Focal granulomatous lesions with formation of foreign body-type MGCs No granulomas No granulomas

Disclosure:

H. Sekine,
None;

T. Machida,
None;

N. Sakamoto,
None;

E. Suzuki,
None;

X. Zhang,
None;

C. Reilly,
None;

G. S. Gilkeson,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/irf-1-deficient-lupus-prone-mrllpr-mice-show-reduced-glomerulonephritis-but-develop-severe-interstitial-nephritis-renal-vasculitis-and-pulmonary-granulomas-with-propensity-for-th2-polarity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology